SuperworthCDT Equity CDT
- Market cap
- $4.1K
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | n/a | n/a | $128K | $25K | $3.1M | $132K | $916K+616% | $1.9M+7340% | $1.5M−51% | $746K+465% | $778K−15% | $302K−84% |
| SG&A | $430K−45% | $2.3M+36% | $2.8M+87% | $3.1M+251% | $2.7M+532% | $3.4M+45% | $2.7M−5% | $3.1M−1% | $5.5M+102% | $20.4M+504% | $2.9M+7% | $2.7M−13% |
| −$430K−54% | −$2.4M+45% | −$3M+95% | −$3.1M+254% | −$5.8M+1251% | −$3.5M+45% | −$3.6M+22% | −$5M+58% | −$7M+21% | −$21.2M+502% | −$3.7M+1% | −$3M−39% | |
| Interest expense | $47K | n/a | $119K+19% | $119K | $309K+557% | −$507K | $176K+48% | $57K−52% | $100K−68% | $0 | $49K−72% | $17K−70% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | $2.6M | $245K−57% | −$3.6M+112% | −$5.4M+211% | −$6.5M | −$2.4M | −$4.8M+34% | −$6M+12% | −$7.1M+10% | −$21.3M+786% | −$4.1M−15% | −$4.6M−23% |
| $750000.00 | n/a | −$3607500.00+60% | −$5466.50−100% | −$5559875.00 | −$1612500.00 | −$917567.50−75% | −$273.50−95% | −$82250.00−99% | n/a | −$1390.00−100% | −$217.75−20% | |
| 1+105% | n/a | 1+14% | 985+112092% | 1+32% | 1 | 5+426% | 22K+2138% | 87+7347% | n/a | 2.9K+56306% | 21.3K−3% |
EPS, diluted: Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x100).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest CDT Equity's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CDTCDT Equity | $4.1K | n/m | n/a | n/m | n/m | n/m | |
| SBFMSunshine Biopharma | $581.6K | n/m | n/a | 0.0× | −3% | −16.5% | |
| DCOYDecoy Therapeutics | $635.5K | n/m | n/a | n/m | n/m | n/m | |
| JAGXJaguar Health | $702.9K | n/m | n/a | 0.0× | +136% | n/m | |
| LABTLakewood-Amedex Biotherapeutics | $734.6K | n/m | n/a | n/m | n/m | n/m | |
| NXTSNexentis Technologies | $761.8K | n/m | n/a | n/m | n/m | n/m | |
| VBIOValion Bio | $834.3K | n/m | n/a | n/m | n/m | n/m | |
| ARTLArtelo Biosciences | $1.3M | n/m | n/a | n/m | n/m | n/m | |
| LNAILunai Bioworks | $1.5M | n/m | n/a | n/m | n/m | n/m | |
| GNPXGenprex | $1.5M | n/m | n/a | n/m | n/m | n/m | |
| GOVXGeoVax Labs | $1.5M | n/m | n/a | n/a | −100% | n/a | |
| Peer median | $798.1K | n/a | n/a | 0.0× | −3% | −16.5% |
More on CDT Equity
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .